Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 560Carcinoma, Non-Small-Cell Lung 517Prostatic Neoplasms 336Colorectal Neoplasms 273Neoplasms 269Multiple Myeloma 267Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 211Neoplasm Metastasis 205Carcinoma, Hepatocellular 198Melanoma 175Triple Negative Breast Neoplasms 174Pancreatic Neoplasms 172Recurrence 153Ovarian Neoplasms 152Lymphoma 142Glioblastoma 136Brain Neoplasms 134Sarcoma 131Carcinoma, Renal Cell 129Lymphoma, Large B-Cell, Diffuse 126Leukemia, Lymphocytic, Chronic, B-Cell 126Stomach Neoplasms 125Head and Neck Neoplasms 125Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 109Myelodysplastic Syndromes 104Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenal Gland Diseases × 1 year × Clear all
NCT05370521 2025-10-09

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Spruce Biosciences

Phase 2 Terminated
27 enrolled 18 charts

Adrenal Gland Diseases, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡